Develop radioligand therapies for cancer treatment. Focus on precision medicine and targeted therapies. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
This is an established company with proven profits.
Red columns mark years that ended in a loss.
If every debt were paid off today, $525.2M would still be left in the vault — a solid cushion for hard times.
The market pays 13.6× for every dollar of annual profit — cheap, which is either an opportunity or a warning.
Analysts' average target sits 10% above today's price.
The stock trades 23% below its peak. The market has trimmed its expectations for the company.
The net profit margin is 43% — that slice of every sale is the company’s cushion in hard quarters.
There is $525.2M in the vault; even if every debt were paid off, $525.2M would remain.
It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.
Our checks did not surface a specific risk to flag here. That is not the same as there being none.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.